NEOK Bio, Inc.
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors (NCT07612189) | NEOK Bio, Inc. | 2026-04-22 |
| A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors (NCT07612176) | NEOK Bio, Inc. | 2026-04-21 |
Track NEOK Bio, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.